Literature DB >> 10452772

Protamine allergy as a complication of insulin hypersensitivity: A case report.

M E Bollinger1, R G Hamilton, R A Wood.   

Abstract

BACKGROUND: Although most patients receiving insulin produce insulin-specific IgE, significant allergic symptoms develop in very few of them. Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity. The case of a 19-year-old woman with insulin-dependent diabetes and regular and NPH insulin hypersensitivity is presented.
OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose. She underwent a standard protocol for insulin desensitization twice in a 2-month period, with persistence in her symptoms. She was found to have high protamine-specific, as well as insulin-specific, IgE levels, and because of her poor response to regular insulin desensitization, she was desensitized to both regular and NPH insulin.
RESULTS: Dual desensitization resulted in marked improvement in her symptoms. The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin. She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives.
CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy. These patients may require protamine/NPH desensitization, an alternative insulin preparation, or both.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452772     DOI: 10.1016/s0091-6749(99)70394-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Recurrent generalised urticaria at insulin injection sites.

Authors:  A H Sackey
Journal:  BMJ       Date:  2000-12-09

2.  Case files of the Harvard Medical Toxicology Fellowship at Children's Hospital Boston: an insulin overdose.

Authors:  Aaron Benjamin Skolnik; Michele Burns Ewald
Journal:  J Med Toxicol       Date:  2010-12

Review 3.  Allergic reactions to human insulin: a review of current knowledge and treatment options.

Authors:  Baris Akinci; Serkan Yener; Firat Bayraktar; Sena Yesil
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

4.  Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin.

Authors:  Victor Matheu; Eva Perez; Marta Hernández; Elisa Díaz; Ricardo Darias; Abel González; Jose C García; Inmaculada Sánchez; Laura Feliciano; Agueda Caballero; Fernando de la Torre
Journal:  Clin Mol Allergy       Date:  2005-12-23

5.  Successful management of insulin allergy and autoimmune polyendocrine syndrome type 4 with desensitization therapy and glucocorticoid treatment: a case report and review of the literature.

Authors:  Joselyn Rojas; Marjorie Villalobos; María Sofía Martínez; Mervin Chávez-Castillo; Wheeler Torres; José Carlos Mejías; Edgar Miquilena; Valmore Bermúdez
Journal:  Case Reports Immunol       Date:  2014-11-19

6.  International Consensus (ICON): allergic reactions to vaccines.

Authors:  Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-09-16       Impact factor: 4.084

Review 7.  A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.

Authors:  Vaisnevee Sugumar; Kuan Ping Ang; Ahmed F Alshanon; Gautam Sethi; Phelim Voon Chen Yong; Chung Yeng Looi; Won Fen Wong
Journal:  Pharmaceutics       Date:  2022-07-04       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.